Clinical Trial Update: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pritelivir for acyclovir-resistant mucocutaneous herpes simplex virus infections in immunocompromised subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Simplex Virus Infection

Drugs mentioned

• Pritelivir (pritelivir)

Snippet

Sponsor: AiCuris Anti-infective Cures AG | Conditions: HSV Infection | Phase 3 | Status: COMPLETED